stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) EPS (diluted)
Indivior Pharmaceuticals Inc.'s EPS (diluted) for fiscal 2025 was $1.64, up 3,017.9% from $0.05 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.58. Over the past ten years it has ranged from −$1.00 (fiscal 2020) to $1.85 (fiscal 2018); the current reading is higher than 91% of that period. Indivior Pharmaceuticals Inc. ranks 6th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.64 | 3,017.87% |
| FY2024 | $0.05 | — |
| FY2023 | −$0.94 | — |
| FY2022 | −$0.38 | — |
| FY2021 | $1.35 | — |
| FY2020 | −$1.00 | — |
| FY2019 | $0.90 | (51.35%) |
| FY2018 | $1.85 | 362.50% |
| FY2017 | $0.40 | 60.00% |
| FY2016 | $0.25 | (83.87%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.12 | 14.59% |
| Jun 2026 | $0.98 | 42.03% |
| Mar 2026 | $0.69 | (12.66%) |
| Dec 2025 | $0.79 | 139.39% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $4.06 |
| SUPN Indivior Pharmaceuticals Inc. | $3.58 |
| LQDA Liquidia Corporation compare | $1.37 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $1.30 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $0.52 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ALKS Alkermes plc compare | −$0.01 |
| HIMS Hims & Hers Health, Inc. compare | −$0.63 |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$1.43 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SUPN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement